...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Medical Journal >Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial
【24h】

Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial

机译：在未经调查的消化不良的初级保健患者中治疗幽门螺杆菌感染：加拿大成人消化不良经验治疗-幽门螺杆菌阳性（CADET-Hp）随机对照试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective To determine whether a "test for Helicobacter pylori and treat" strategy improves symptoms in patients with uninvestigated dyspepsia in primary care. Design Randomised placebo controlled trial. Setting 36 family practices in Canada. Participants 294 patients positive for H pylori (~(13)C-urea breath test) with symptoms of dyspepsia of at least moderate severity in the preceding month. Intervention Participants were randomised to twice daily treatment for 7 days with omeprazole 20 mg, metronidazole 500 mg, and clarithromycin 250 mg or omeprazole 20 mg, placebo metronidazole, and placebo clarithromycin. Patients were then managed by their family physicians according to their usual care. Main outcome measures Treatment success defined as no symptoms or minimal symptoms of dyspepsia at the end of one year. Societal healthcare costs collected prospectively for a secondary evaluation of actual mean costs. Results In the intention to treat population (n=294), eradication treatment was significantly more effective than placebo in achieving treatment success (50% v 36%; P=0.02; absolute risk reduction=14%; number needed to treat=7, 95% confidence interval 4 to 63). Eradication treatment cured H pylori infection in 80% of evaluable patients. Treatment success at one year was greater in patients negative for H pylori than in those positive for H pylori (54% v 39%; P=0.02). Eradication treatment reduced mean annual cost by $C53 (- 86 to 180) per patient. Conclusions A "test for H pylori with ~(13)C-urea breath test and eradicate" strategy shows significant symptomatic benefit at 12 months in the management of primary care patients with uninvestigated dyspepsia.
机译：目的确定“幽门螺杆菌测试和治疗”策略是否可以改善初级保健中未调查消化不良的患者的症状。设计随机安慰剂对照试验。在加拿大设定36种家庭习俗。参与者294例幽门螺杆菌阳性（〜（13）C-尿素呼气试验）阳性，前一个月的消化不良症状至少为中度。参加者被随机分为每天两次，每天两次，分别为奥美拉唑20 mg，甲硝唑500 mg和克拉霉素250 mg或奥美拉唑20 mg，安慰剂甲硝唑和安慰剂克拉霉素。然后由他们的家庭医生按照常规护理对患者进行治疗。主要结局指标治疗成功的定义为在一年结束时无消化不良症状或症状轻微。前瞻性收集的社会医疗保健成本用于实际平均成本的二次评估。结果为了治疗人群（n = 294），根除治疗比安慰剂有效得多（50％vs 36％； P = 0.02；绝对风险降低= 14％；需要治疗的人数= 7， 95％置信区间4到63）。根除治疗治愈了80％的可评估患者的幽门螺杆菌感染。幽门螺杆菌阴性的患者一年的治疗成功率高于幽门螺杆菌阳性的患者（54％vs 39％； P = 0.02）。根除治疗使每位患者的年均费用降低了C53美元（从86降至180）。结论“采用〜（13）C-尿素呼气试验并根除幽门螺杆菌测试”策略在未调查消化不良的初级保健患者的治疗中显示出在12个月时明显的症状获益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号